Ubs Asset Management Americas Inc Alnylam Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 706,231 shares of ALNY stock, worth $174 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

706,231

Previous 835,413 15.46%

Holding current value

$174 Million

Previous $203 Million 4.3%

% of portfolio

0.05%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $30.2 Million - $37.1 Million	-129,182 Reduced 15.46%	706,231 $194 Million
Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $11 Million - $19 Million	76,763 Added 10.12%	835,413 $203 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $2.58 Million - $3.49 Million	17,589 Added 2.37%	758,650 $113 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $5.06 Million - $6.57 Million	-33,415 Reduced 4.31%	741,061 $142 Million
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $17.2 Million - $21.3 Million	100,598 Added 14.93%	774,476 $137 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $2.91 Million - $3.76 Million	15,958 Added 2.43%	673,878 $135 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $10.1 Million - $13.1 Million	54,388 Added 9.01%	657,920 $156 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $1.43 Million - $2.39 Million	10,310 Added 1.74%	603,532 $121 Million
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $1.44 Million - $2.02 Million	-11,943 Reduced 1.97%	593,222 $86.5 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $4.52 Million - $6.18 Million	-35,545 Reduced 5.55%	605,165 $98.8 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $775,780 - $1.02 Million	-4,862 Reduced 0.75%	640,710 $109 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $3.79 Million - $4.64 Million	22,344 Added 3.59%	645,572 $122 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $5.44 Million - $7.48 Million	-42,301 Reduced 6.36%	623,228 $106 Million
Q1 2021 May 14, 2021	SELL	$126.83 - $175.69 $5.06 Million - $7.01 Million	-39,906 Reduced 5.66%	665,529 $94 Million
Q4 2020 Mar 01, 2021	SELL	$122.97 - $147.0 $2.19 Million - $2.62 Million	-17,790 Reduced 2.46%	705,435 $91.7 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $13.9 Million - $18.9 Million	-114,402 Reduced 13.66%	723,225 $105 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $650,374 - $976,342	6,241 Added 0.75%	837,627 $124 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $718,607 - $1.03 Million	7,717 Added 0.94%	831,386 $90.5 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $2.41 Million - $4.02 Million	32,360 Added 4.09%	823,669 $94.9 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $12.3 Million - $15.2 Million	-173,457 Reduced 17.98%	791,309 $63.6 Million
Q2 2019 Aug 15, 2019	SELL	$65.86 - $92.79 $12.7 Million - $17.9 Million	-193,372 Reduced 16.7%	964,766 $0
Q1 2019 May 14, 2019	SELL	$72.76 - $93.45 $18.9 Million - $24.2 Million	-259,352 Reduced 18.3%	1,158,138 $0
Q4 2018 Feb 13, 2019	BUY	$62.67 - $88.33 $6.05 Million - $8.53 Million	96,532 Added 7.31%	1,417,490 $103 Million
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $3.29 Million - $4.62 Million	-37,641 Reduced 2.77%	1,320,958 $0
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $1.54 Million - $1.88 Million	17,428 Added 1.3%	1,358,599 $0
Q1 2018 May 14, 2018	SELL	$115.92 - $148.54 $6.15 Million - $7.88 Million	-53,042 Reduced 3.8%	1,341,171 $0
Q4 2017 Feb 09, 2018	BUY	$114.49 - $139.98 $3.41 Million - $4.17 Million	29,816 Added 2.19%	1,394,213 $0
Q3 2017 Nov 13, 2017	BUY	$72.53 - $118.27 $99 Million - $161 Million	1,364,397	1,364,397 $0

Others Institutions Holding ALNY

# of Institutions

645

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.22M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Alnylam Pharmaceuticals, Inc. Transaction History